CDK4 and Huntington disease: There are insufficient data on treating HD patients with letrozole, paclitaxel, cyclophosphamide, and all newer medical products: CDK4/6 inhibitors, neratinib, PARP inhibitors, T-DM1, pertuzumab, and atezolizumab.